• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Verinata study published in Obstetrics & Gynecology journal

Verinata study published in Obstetrics & Gynecology journal

February 27, 2012
CenterWatch Staff

Obstetrics & Gynecology (Green journal) published full data from Verinata Health’s prospective, blinded, multi-center clinical validation study to detect fetal chromosomal aneuploidies across the entire genome using its verifi prenatal test.

The publication, titled "Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing," was selected as Editor's Choice of the peer-reviewed journal. Full study results are available in the online version, and a print version will be available in the May 2012 issue.

"When we designed this study, it was imperative that it emulate actual clinical practice, including all high-risk pregnant women, and importantly, detecting aneuploidy across the entire genome, where the genetic information about the fetus is unknown prior to this test," said Caren L. Mason, CEO of Verinata Health. "The clinical study demonstrated 100% specificity (no false positives) in the most prevalent trisomies.”

Verinata's proprietary verifi non-invasive prenatal test will include the detection of Down syndrome (trisomy 21), Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13) in the initial launch configuration.

Additional technical papers covering Verinata's methods in practice and continuing improvement in sequencing results are pending.

The verifi prenatal test will be available to clinicians in the U.S. March 1 and will include simplified sample collection methods, streamlined test reporting and less than a 1% no call rate. Verinata intends to expand the capabilities of the verifi prenatal test later in 2012.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing